Enterome

Enterome is pioneering the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system – the Microbiome-Immunoinflammation Axis. Enterome is using this expertise to generate a pipeline of clinical and pre-clinical candidates (small molecules and peptides) with a focus on cancer, autoimmune, inflammatory and metabolic diseases. Enterome’s strategy is to develop new pharmaceuticals that deliver significantly improved treatments that benefit patients globally and also generate value for its shareholders.